Guardant Health has
advanced our technology
to include screening for early
CRC detection1,2
For a decade, Guardant Health has been dedicated to supporting patients with cancer across the continuum of care3
-
SCREENING AND EARLY DETECTION*
Diagnosis
ECLIPSE STUDY
A registrational study validated Shield for CRC screening in over 10,000 average-risk patients.3,5
-
EARLY-STAGE CANCER*
Residual disease detection
and recurrence surveillance (commercially available since 20213)
Surgery
Recurrence
-
ADVANCED CANCER*
Treatment selection and optimization (commercially available since 20143,4†)
Progression
200,000 patients tested & 260+ peer-reviewed publications3
-
In early- and late-stage cancer
National Cancer Institute and National Comprehensive Cancer Network cancer centers use Guardant Health’s existing blood-based tests to inform treatment decisions for patients with early- and late-stage cancer 3
Patient Timeline‡
*Disclaimer: Shield, Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 tests were developed, and their performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. Guardant360 refers to Guardant360 Laboratory Developed Test (LDT). These tests have not been cleared or approved by the US FDA.
†Guardant360 has been commercially available since 2014.3
‡Patient timeline shown for illustrative purposes only.
See how we are
working to give
patients with cancer
more time1,6
See how we are working to give patients with cancer more time1,6
Now, we have developed an accurate blood-based test, Shield™, that can increase CRC screening compliance1,2,7
Sign up to receive the latest updates on ShieldTM
- The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
- Patients with an "abnormal signal detected" Shield test result should be referred for colonoscopic evaluation
- A "normal signal detected" Shield test result does not preclude the presence of colorectal neoplasia, and patients should continue participating in guideline-recommended screening programs
- Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
